Access Statistics for Aidan Hollis

Author contact details at EconPapers.

Working Paper File Downloads Abstract Views
Last month 3 months 12 months Total Last month 3 months 12 months Total
A Contractual Approach to the Gray Market 0 0 0 426 1 1 1 2,100
Complementarity, Competition and Institutional Development: The Irish Loan Funds through Three Centuries 0 0 1 295 0 1 5 1,320
Exclusivity Restrictions in Markets with Adverse Selection: The Case of Extended Warranties 0 0 0 106 0 0 0 842
Generic drug pricing in Canada: components of the value-chain 0 2 5 106 0 2 6 328
Microcredit in Pre-Famine Ireland 0 0 0 335 0 2 9 1,770
New Approaches to Rewarding Pharmaceutical Innovation 0 0 1 94 0 0 1 165
Privacy, Driving Data and Automobile Insurance: An Economic Analysis 0 0 0 70 1 1 2 245
Privacy, Driving Data and Automobile Insurance: An Economic Analysis 0 0 0 0 0 0 3 282
Subsidizing the Competition 0 0 0 134 0 0 1 682
The Evolution of A Microcredit Institution: The Irish Loan Funds, 1720 - 1920 0 0 1 324 0 2 4 1,589
Total Working Papers 0 2 8 1,890 2 9 32 9,323


Journal Article File Downloads Abstract Views
Last month 3 months 12 months Total Last month 3 months 12 months Total
A National Formulary for Canada 0 0 0 546 0 0 1 4,111
A contractual approach to the gray market 0 0 1 123 0 0 7 407
An Optional Delinked Reward System: Making Pharmaceutical Innovation Work for Everyone 0 0 0 0 0 0 3 4
Climate impact auctions: an underused tool for green subsidies in the Global South 0 0 0 0 0 0 0 0
Co-authorship and the output of academic economists 0 0 1 72 0 0 2 249
Competition policy in open economies 0 0 0 32 1 1 2 168
Der Green Impact Fund for Technology 0 0 2 3 0 2 7 14
Generic Drug Pricing and Procurement: A Policy for Alberta 0 0 0 4 0 0 1 18
Governance of electricity transmission systems 0 0 0 81 1 1 1 213
How do Brands’ “Own Generics” Affect Pharmaceutical Prices? 1 1 1 191 1 2 2 486
How will recent trade agreements that extend market protections for brand-name prescription pharmaceuticals impact expenditures and generic access in Canada? 0 0 0 2 0 0 0 14
Industrial Concentration, Output, and Trade: An Empirical Exploration 0 0 1 37 0 0 1 104
Making Sure Orphan Drugs Don’t Get Left Behind 0 0 1 3 0 2 4 20
Microcredit in Prefamine Ireland 0 0 1 62 0 1 3 268
Microcredit: What can we learn from the past? 1 2 3 328 1 2 15 971
Microfinance and Famine: The Irish Loan Funds during the Great Famine 0 0 1 98 0 1 5 441
Newton's First Law as Applied to Pharmacies: Why Entry Order Matters for Generics 0 2 6 32 1 4 10 120
Patient income and health innovation 0 0 0 11 0 0 0 38
Predicting patent challenges for small-molecule drugs: A cross-sectional study 0 0 0 0 1 1 1 1
Preliminary Injunctions and Damage Rules in Patent Law 0 0 0 72 0 0 0 331
Price‐cap Regulation, Uncertainty and the Price Evolution of New Pharmaceuticals 0 0 0 9 0 0 1 34
Strategic Implications of Learning by Doing 0 0 0 87 0 0 1 561
Sustainable Financing of Innovative Therapies: A Review of Approaches 0 0 1 15 1 2 5 41
The Anti-Competitive Effects of Brand-Controlled "Pseudo- Generics" in the Canadian Pharmaceutical Market 0 0 0 233 0 3 3 730
The Role of Local Depositors in Controlling Expenses in Small‐Scale Financial Intermediation: An Empirical Analysis 0 0 0 16 0 0 0 83
The economic theory of cost‐effectiveness thresholds in health: Domestic and international implications 0 0 0 2 0 0 2 13
The impact of changing the reference countries on the list prices for patented medicines in Canada: A policy analysis 0 0 0 0 0 0 1 1
The importance of being first: evidence from Canadian generic pharmaceuticals 1 2 6 307 1 3 11 717
The large-scale integration of wind generation: Impacts on price, reliability and dispatchable conventional suppliers 0 0 0 60 1 1 5 163
The life-cycle of a microfinance institution: the Irish loan funds 0 0 2 157 0 1 3 457
The path of least resistance: Paying for antibiotics in non-human uses 0 0 0 6 0 0 1 33
Total Journal Articles 3 7 27 2,589 9 27 98 10,811


Statistics updated 2025-07-04